Article Text

Download PDFPDF
Successful treatment of interstitial pneumonitis with anakinra in a patient with adult-onset Still’s disease
  1. Irene Sollano-Sancho1,
  2. Beatriz Rubio-Cebrian1,
  3. Maria Luisa de la Cruz2,
  4. Blanca San-Jose-Montano3
  1. 1Pharmacy, Hospital Universitario de Móstoles, Móstoles, Spain
  2. 2Faculty of Medicine, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Spain
  3. 3Hospital Universitario de Mostoles Biblioteca de Ciencias de la Salud, Mostoles, Spain
  1. Correspondence to Irene Sollano-Sancho, Pharmacy, Hospital Universitario de Móstoles, 28223 Móstoles, Spain; irene.sollano{at}salud.madrid.org

Abstract

A 29-year-old African woman with active adult-onset Still’s disease (AOSD) that developed at the end of 2018 presented to our hospital in September 2019 with pleuritic right-sided pain and respiratory insufficiency of almost a month’s duration, which had failed to respond to high-dose corticosteroid and antibiotic treatment. A thoracic CT revealed right pleural effusion, multiple consolidations and pulmonary collapse. Besides pulmonary symptoms, the patient had arthralgia, fever, a salmon-coloured rash, leucocytosis and rising inflammatory markers. After an AOSD flare diagnosis was established, intravenous methylprednisolone and painkillers were administered. Due to the severity of the pleural effusion and the lack of response to previous treatments, subcutaneous anakinra was started. Two days after the first dose the patient had almost fully recovered. The success of this case points out the potential effectiveness of anakinra in the prevention of a pulmonary failure and the treatment of a severe intermittent polycyclic pattern of AOSD.

  • clinical pharmacy
  • immunology
  • rheumatology
  • rheumatology
  • respiratory medicine (see thoracic medicine)
  • thoracic medicine
View Full Text

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.